Rajesh Exports says 400 GB data shared with Sebi amid accounting row

Rajesh Exports says 400 GB data shared with Sebi amid accounting row



Rajesh Exports on Thursday pushed back against allegations made by the Securities and Exchange Board of India (Sebi), with its promoter and executive chairman, Rajesh Mehta, claiming that the company has already shared more than 400 GB of data and information with the market regulator and attributing the dispute to a “communication gap” and “confusion” over information submissions.

 


The company also argued that there would be little incentive for a listed entity to inflate revenues while maintaining earnings, as doing so would compress profit margins.

 


Responding to queries from Business Standard following Sebi’s interim order, Mehta said the company had already furnished most of the information sought by the regulator.

 
 


“We have shared over 400 GB of data and information with the market regulator. We have already provided most of the details but there seems to be a communication gap and confusion. We will be clarifying the matter with Sebi and also again sending all the required documents, which we are confident should clarify the matter,” Mehta said.

 


The remarks come days after Sebi, in a 109-page interim order, alleged misreporting in the company’s financial statements amounting to Rs 15.15 trillion, or nearly 99 per cent of its reported revenue. The regulator described the alleged misrepresentation as “unheard of” and barred Mehta from trading in Rajesh Exports securities pending further investigation.

 


Shares of the company — once touted as one of the world’s largest gold jewellery exporters — hit the 5 per cent lower circuit on Thursday to close at Rs 105. The company is now valued at about Rs 3,090 crore, with its valuation declining over 40 per cent so far this year.

 


Meanwhile, the allegations in the Rajesh Exports matter have reignited concerns over corporate governance standards and raised questions about the investment decisions of large institutional shareholders. The spotlight has particularly fallen on state-owned Life Insurance Corporation of India (LIC), which remains the company’s largest public shareholder with a 10.8 per cent stake as of March 2026.

 


LIC’s continued holding in the company despite the stock’s prolonged decline and growing regulatory scrutiny has drawn criticism from governance experts and investors, with several market participants expressing concerns on social media.

 


Proxy advisory firms said the episode raises broader questions about the due diligence processes followed by institutions entrusted with public savings.

 


“LIC owes a huge responsibility to its policyholders. It should undertake rigorous forensic accounting and due diligence before making investments so that companies with fictitious revenues can be identified at an early stage,” said Shriram Subramanian, founder and managing director of InGovern Research Services.

 


Experts said institutional investors should reassess their holdings when credible evidence of accounting irregularities emerges and not wait for regulatory action.

 


Apart from LIC, Mauritius-based Bridge India Fund held an 8.46 per cent stake in Rajesh Exports as of March 2026.

 


“In the case of public financial institutions, which manage public money and typically have robust investment committees and oversight mechanisms, one can reasonably expect heightened vigilance over large investments, especially where they receive information under investment agreements or through periodic investor interactions,” said Prem Rajani, managing partner at Rajani Associates.

 


Questions surrounding Rajesh Exports’ accounts first surfaced in 2023 when the National Stock Exchange sought details on certain investments and cash flows. The exchange’s queries were followed by shareholder complaints to Sebi in 2024.

 


According to Sebi, company funds were routed and layered through personal accounts and related entities without adequate disclosures or supporting documentation. The regulator has also alleged that funds were transferred to Mehta’s personal account for derivatives trading and subsequently recorded in the company’s books as sales and purchase transactions.

 


Separately, Sebi has referred the matter to the National Financial Reporting Authority (NFRA) for examination of the company’s statutory auditors.

 


Rajesh Exports said it would continue to cooperate with the regulator and seek to resolve the matter through further submissions.



Source link

Aurobindo Pharma receives USFDA approval for Tofacitinib Tablets

Aurobindo Pharma receives USFDA approval for Tofacitinib Tablets


Aurobindo Pharma has received a final approval from the US Food
& Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets, 5 mg and 10 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xeljanz Tablets, 5 mg
and 10 mg, of PF Prism C.V.

The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company and will be launched immediately.

 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Jun 04 2026 | 7:16 PM IST



Source link

Aurobindo Pharma receives USFDA approval for Tofacitinib Tablets

Southwest Monsoon has set in over Kerala, says IMD


Southwest Monsoon has set in over Kerala, today the 4th June, 2026, India Meteorological Department of IMD has stated in a latest update. The Southwest Monsoon has further advanced into remaining parts of Southwest & Southeast Arabian Sea, some parts of westcentral & eastcentral Arabian Sea, entire Lakshadweep islands, Kerala & Mahe, some parts of Karnataka, Tamil Nadu, remaining parts of Comorin area, southeast Bay of Bengal and some more parts of southwest, westcentral, eastcentral and northeast Bay of Bengal today the 4th June, 2026.

Powered by Capital Market – Live News

 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Jun 04 2026 | 5:31 PM IST



Source link

Aurobindo Pharma receives USFDA approval for Tofacitinib Tablets

CMR Green Technologies IPO subscribed 9.59 times


The offer received bids for 22.10 crore shares as against 2.30 crore shares on offer.

CMR Green Technologies received bids for 22,10,69,862 shares as against 2,30,43,930 shares on offer, according to stock exchange data at 17:00 IST on Thursday (4 June 2026). The issue was subscribed 9.59 times.

The issue opened for bidding on 3 June 2026 and it will close on 5 June 2026. The price band of the IPO is fixed between Rs 182 and 192 per share. An investor can bid for a minimum of 78 equity shares and multiples thereof.

The offer comprises a net offer for sale of up to 3,28,58,323 equity shares. The offer for sale by the selling shareholders comprises up to 49,59,428 shares by Mohan Agarwal, up to 10,00,000 shares by Gauri Shankar Agarwal HUF, up to 5,00,000 by Mohan Agarwal HUF and up to 2,63,98,895 shares by Global Scrap Processors.

 

Ahead of the IPO of CMR Green Technologies on 2 June 2026, the company raised Rs 188.43 crore from anchor investors by allotting 98.14 lakh shares at Rs 192 each to 18 anchor investors.

CMR Green Technologies (CMRG) is engaged in the recycling of non-ferrous metals and produces secondary aluminium and zinc die-casting alloys. Along with non-ferrous metals, the firm also offers aluminium billets serving automotive and non-automotive sectors. These billets, made from recycled aluminium, are raw materials used in extrusion processes to create profiles for various applications. Honda Cars India, Bajaj Auto, Hero MotoCorp, Royal Enfield Motors, and India Yamaha Motor are the major OEM customers of the company. As on December 31, 2025, the company has 784 permanent employees and 3,956 contractual workmen.

For the nine months ended 31 December 2026, the firm recorded a consolidated net profit of Rs 148.09 crore and income from operations of Rs 6,275.52 crore.

Powered by Capital Market – Live News



Source link

Aurobindo Pharma receives USFDA approval for Tofacitinib Tablets

Artificial Electronics appoints Girija Sankar Tripathy as new CFO


Artificial Electronics Intelligent Material has appointed Girija Sankar Tripathy as its Chief Financial Officer (CFO) with effect from 3 June 2026.

Tripathy is a finance professional with over 15 years of experience in budgeting, financial planning, corporate reporting, management information systems (MIS), and financial control across large-scale manufacturing organisations. He also possesses expertise in cost management and product costing, helping businesses improve operational efficiency and profitability.

Throughout his career, he has successfully led project management initiatives, strengthened internal control frameworks, and driven process improvement programmes to enhance financial governance, analytical capabilities, and decision-making effectiveness.

He is recognised for his ability to collaborate closely with senior management and business leaders, providing actionable financial insights, optimising reporting processes, and aligning financial strategies with organisational objectives to support sustainable growth and value creation.

 

Separately, the company announced the resignation of Muthusamy Palanisamy from the position of Chief Financial Officer, effective 3 June 2026.

According to the company, the resignation is part of a broader restructuring and reorganisation of management functions at the group level, following decisions taken by the board of directors.

Artificial Electronics Intelligent Material is engaged in the business of developing & providing software consultancy services.

The company reported a consolidated net profit of Rs 11.92 crore in Q4 FY26, compared with Rs 0.53 crore in the corresponding quarter of the previous fiscal. Revenue from operations surged to Rs 46.01 crore in Q4 FY26 from Rs 4.11 crore reported in Q4 FY25.

The counter shed 0.26% to end at Rs 114.75 on the BSE.

Powered by Capital Market – Live News



Source link

Aurobindo Pharma receives USFDA approval for Tofacitinib Tablets

INR settles lower as prolonged West Asia crisis poses a major risk for India; RBI eyed


The Indian rupee depreciated 7 paise to close at 95.83 (provisional) against the US dollar on Thursday, as heightened geopolitical tensions between the US and Iran drove energy volatility and aggressive safe-haven buying. The prolonged West Asia crisis poses a major risk for India, which relies heavily on energy imports. Market participants are now turning their attention to the Reserve Bank of India’s MPC rate decision on June 5, as inflation, growth and the rupee are under focus. The six-member MPC, headed by RBI Governor Sanjay Malhotra, will announce its decision on June 5. Indian equity benchmarks ended flat but resilient today, recovering from early intraday losses. The NSE Nifty 50 closed marginally higher by 10.95 points (0.05%) at 23,416.55, while the BSE Sensex inched up 13.84 points (0.02%) to finish at 74,360.01. The primary catalysts for the market recovery were breaking news of potential tax concessions for foreign institutional investors (FIIs) and tentative signs of easing in global geopolitical tensions.

 

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Jun 04 2026 | 5:16 PM IST



Source link

YouTube
Instagram
WhatsApp